The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new biotechnology methods instead to spur innovation in the pharmaceutical ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min An Austin startup that has been ...
Following successful small-animal trials that confirmed bioequivalence, BioNxt is now taking the final preclinical step to prepare its sublingual Cladribine formulation for human testing. The upcoming ...
One in four safety-related failures are due to central nervous system (CNS) toxicity. But because conventional models used in preclinical Good Laboratory Practice (GLP) safety testing fail to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results